Edgewise Therapeutics Inc.
EWTX | NASDAQ
$45.16
+$0.52 (+1.16%)
Sep 22, 2026, 1:02 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 2.27M | n/a | n/a | n/a | n/a | 185K |
Gross Profit | -2.27M | n/a | n/a | n/a | n/a | -185K |
Operating Income | -191.41M | -158.83M | -114.36M | -71.66M | -43.22M | -17.19M |
Interest Income | 23.61M | 25.02M | 14.19M | 2.66M | 402K | 69K |
Pretax Income | -167.8M | -133.81M | -100.16M | -67.64M | -42.81M | -17.12M |
Net Income | -167.8M | -133.81M | -100.16M | -67.64M | -42.81M | -17.05M |
Selling & General & Admin | 40.02M | 31.87M | 23.45M | 17.63M | 11.03M | 2.21M |
Research & Development | 151.39M | 126.97M | 90.91M | 54.03M | 32.19M | 14.8M |
Other Expenses | -2.27M | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 189.14M | 158.83M | 114.36M | 71.66M | 43.22M | 17.01M |
Interest Expense | n/a | n/a | n/a | 4.02M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 191.41M | 158.83M | 114.36M | 71.66M | 43.22M | 17.19M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 102.93M | 92.41M | 63.72M | 53.59M | 49.5M | 49.22M |
Shares Outstanding (Diluted) | 102.93M | 92.41M | 63.72M | 53.59M | 49.5M | 49.22M |
EPS (Basic) | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 |
EPS (Diluted) | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 |
EBITDA | -165.53M | -131.52M | -98.43M | -63.08M | -42.54M | -17.01M |
EBIT | -167.8M | -133.81M | -100.16M | -63.62M | -42.81M | -17.19M |
Depreciation & Amortization | 2.27M | 2.29M | 1.73M | 538K | 272K | 185K |
Add to Watchlist
Select watchlists to add or remove EWTX